Zoetis Stock Earnings Reports

Zoetis reported Q1 2026 revenue of $2.3B (flat on an organic operational basis) and adjusted net income of $646M (up ~1% organic). Geographic/species performance was bifurcated: International grew ~10% (organic) and livestock grew 12% (broad-based strength), while U.S. revenue declined 8% with U.S. companion animal down ~11%. Key drivers of the companion animal weakness were: softer clinic traffic, increased pet-owner price sensitivity, intensified competitor promotions (especially in dermatology and parasiticides), and some generic entry into non-core blockbusters (Convenia, Cerenia). Diagnostics and certain OA Pain / livestock products showed pockets of resilience and growth. Management said some of the quarter’s results were affected by timing shifts from a fiscal-year alignment (roughly $100M shifted into Q1), and excluding that shift the underlying organic decline in Q1 would have been larger. Actions: management is tightening discretionary spend, launching a company-wide cost and productivity program, sharpening commercial execution (vet engagement, DTC, affordability/loyalty, localized market plans), accelerating “science to scale” and targeted BD (Neogen animal genomics announced), and prioritizing near-term launches and lifecycle innovations. Updated full-year 2026 guidance (organic operational): revenue growth 2%–5% and adjusted net income growth 2%–6%; adjusted EPS range $6.85–$7.00 (adjusted) and reported EPS $6.35–$6.50. Management expects continued pressure in companion animal in the near term but believes stabilization is occurring in several franchises and that the pipeline (multiple potential blockbusters) will drive longer-term growth beginning toward the end of 2027 and into 2028.